True sale confusion could put brakes on CMBS
A clash over the accounting treatment of risk retention notes has thrown the US CMBS market into flux, with uncertainty over the issue throwing into question the capital treatment and profitability of certain CMBS deals issued since the rule went into effect last year. David Bell reports.
Please take a trial or subscribe to access this content.
Contact our subscriptions team to discuss your access: email@example.com